Abstract | OBJECTIVE: METHODS: In a prospective randomized controlled clinical trial, 90 patients with AECOPD of RPHF syndrome were randomly assigned to 3 groups, TRQI and controls A and B, each with 30 cases. The TRQI group was administered with the intravenous injections of 20 mL TRQI once a day and conventional Western medicine treatment. Control group A was administered with the intravenous injection of 15 mg ambroxol hydrochloride twice a day and conventional Western medicine treatment, and control group B was administered with conventional Western medicine treatment only. The treatments were administered for 10 days. Chinese medical symptoms and signs were scored, and plasma concentrations of interleukin (IL)-8 and neutrophil elastase (NE) were recorded. RESULTS: (1) The Chinese medical symptoms ( cough, sputum amount, expectoration, dyspnea and fever) and signs (tongue and pulse) improved significantly in the TRQI group (P<0.05 or P<0.01), and improvements in cough, sputum amount and expectoration were better in the TRQI group than control group B (P<0.05); there was no significant difference between the TRQI group and control group A (P>0.05). The sign of tongue was also improved significantly in the TRQI group (P<0.05). (2) The overall effects in the TRQI group and control group A were significantly better than in control group B (P<0.05), with no significant differences between the TRQI group and control group A (P>0.05). There was no significant difference in the total effective rate among the three groups (P>0.05). (3) After treatment, the plasma concentrations of IL-8 and NE decreased in the TRQI group and control group A (P<0.05), and the concentration of IL-8 in control group B decreased (P<0.05). The difference in IL-8 was greater in the TRQI group than in control group A and B before and after treatment, and the change in NE was greater in control group A than in the TRQI group and control group B, but there was no statistical significance among the three groups with regards to the change in IL-8 or NE (P>0.05). CONCLUSION: TRQI could improved the Chinese medical signs and symptoms in the patients with AECOPD, possibly because of the decreasing plasma levels of IL-8 and NE which could improve response to airway inflammation and mucus hypersecretion.
|
Authors | Wen Li, Bing Mao, Gang Wang, Lei Wang, Jing Chang, Ying Zhang, Mei-hua Wan, Jia Guo, Yu-qiong Zheng |
Journal | Chinese journal of integrative medicine
(Chin J Integr Med)
Vol. 16
Issue 2
Pg. 131-7
(Apr 2010)
ISSN: 1672-0415 [Print] China |
PMID | 20473738
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Drugs, Chinese Herbal
- tanreqing
|
Topics |
- Acute Disease
- Aged
- Body Temperature
(drug effects)
- Drugs, Chinese Herbal
(administration & dosage, adverse effects)
- Female
- Follow-Up Studies
- Hot Temperature
- Humans
- Injections
- Male
- Medicine, Chinese Traditional
- Middle Aged
- Mucus
(drug effects)
- Pulmonary Disease, Chronic Obstructive
(complications, drug therapy)
- Syndrome
- Treatment Outcome
|